natgillin/translations-raw huggingface dataset:
It is available as a powder (4mg) and solvent, and as a concentrate (4mg/5ml), both of which are made up into a solution for infusion (drip into a vein), and as a pre-prepared solution for infusion (4mg/100ml). 
Na voljo je v obliki praška (4 mg) in vehikla ter koncentrata (4 mg/5 ml), ki se oba uporabita za pripravo raztopine za infundiranje (kapalne infuzije v veno), in kot predhodno pripravljene raztopine za infundiranje (4mg/100 ml).
A risk management plan has been developed to ensure that Zometa is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Zometa je bil pripravljen načrt obvladovanja tveganj.
Osteonecrosis of the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth) has been reported uncommonly (seen in between 1 and 10 patients in 1,000). 
O osteonekrozi čeljustnice (poškodbi čeljustnice, ki lahko povzroči bolečine, oteklost v ustih ali majanje zob) so poročali občasno (opaženo pri 1 do 10 bolnikih od 1 000).
The CHMP decided that Zometa's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Zometa večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
In the third study, Zometa was as effective as pamidronate: 44% of the patients receiving Zometa had at least one skeletal event, compared with 46% of those receiving pamidronate. 
V tretji študiji je bilo zdravilo Zometa enako učinkovito kot pamidronat: 44 % bolnikov, ki so prejemali zdravilo Zometa, je imelo vsaj en z okostjem povezan dogodek v primerjavi s 46 % tistih, ki so prejemali pamidronat.
The most common side effect with Zometa (seen in more than 1 patient in 10) is hypophosphataemia (low blood phosphate levels). 
Najpogostejši neželeni učinek zdravila Zometa (opažen pri več kot 1 bolniku od 10) je hipofosfatemija (nizka raven fosfatov v krvi).
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zometa, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zometa. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
In addition, the company that markets Zometa will provide a card to inform patients about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they experience symptoms. 
Poleg tega bo družba, ki trži zdravilo Zometa, pripravila kartico, s katero bo bolnike seznanila s tveganjem pojava osteonekroze čeljustnice in jih pozvala, naj v primeru pojava simptomov poiščejo zdravniško pomoč.
Looking at the results of the two studies together, 88% of the patients receiving Zometa had normal calcium levels within 10 days after treatment, compared with 70% of those receiving pamidronate. 
Na podlagi rezultatov obeh študij skupaj je mogoče ugotoviti, da je bila pri 88 % bolnikov, ki so prejemali zdravilo Zometa, raven kalcija v 10 dneh po zdravljenju normalna v primerjavi s 70 % tistih, ki so prejemali pamidronat.
In patients with hypercalcaemia, Zometa was more effective than pamidronate. 
Pri bolnikih s hiperkalciemijo je bilo zdravilo Zometa učinkovitejše od pamidronata.
Zometa should not be used in pregnant or breastfeeding women. 
Prav tako ga ne smejo uporabljati nosečnice in doječe ženske.
In the first two studies of patients with bone metastases, the number of patients who developed a new skeletal event was lower with Zometa (33 to 38%) than with placebo (44%). 
V prvih dveh študijah pri bolnikih s kostnimi metastazami, ki so prejemali zdravilo Zometa, je bilo število bolnikov, pri katerih se je razvil nov, z okostjem povezan dogodek, manjše kot pri tistih, ki so prejemali placebo (od 33 do 38 % v primerjavi s 44 %).
Zoledronic acid 
Zometa zoledronska kislina
The main measure of effectiveness was the number of patients who developed at least one new ‘skeletal event' over 13 months. 
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se je v 13 mesecih pojavil vsaj en nov z okostjem povezan dogodek.
Zometa must not be used in people who are hypersensitive (allergic) to zoledronic acid, other bisphosphonates or any of the other ingredients. 
Zdravila Zometa ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) zoledronsko kislino, druge difosfonate ali katero koli drugo sestavino zdravila.
Why has Zometa been approved? 
Zakaj je bilo zdravilo Zometa odobreno?
Zometa has been studied in over 3,000 adults with bone metastases in three main studies looking at its ability to prevent bone damage. 
Zdravilo Zometa so proučevali v treh glavnih študijah pri več kot 3 000 bolnikih s kostnimi metastazami, v katerih so raziskali njegovo sposobnost pri preprečevanju poškodb kosti.
When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. A lower dose is recommended for patients with bone metastases (when cancer has spread to the bone) if they have mild to moderate problems with their kidneys. 
Pri uporabi zdravila za preprečevanje z okostjem povezanih zapletov se infundiranje lahko ponovi vsake tri do štiri tedne, bolniki pa morajo prejemati tudi dodatek kalcija in vitamina D. Pri bolnikih s kostnimi metastazami (rakom, ki se je razširil na kosti), ki imajo blage do zmerne težave z ledvicami, je priporočljiv nižji odmerek zdravila.
This leads to less bone loss. 
S tem se zmanjša izguba kostnega mase.
Zometa is a medicine that contains the active substance zoledronic acid. 
Zometa je zdravilo, ki vsebuje zdravilno učinkovino zoledronska kislina.
For the full list of all side effects reported with Zometa, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Zometa, glejte navodilo za uporabo.
Zometa must only be used by a doctor who has experience in the use of this type of medicine given into a vein. 
Zdravilo Zometa smejo uporabljati le zdravniki z izkušnjami z uporabo te vrste zdravil za intravensko uporabo.
Zometa has also been compared with pamidronate in two main studies involving a total of 287 adults with hypercalcaemia caused by tumours. 
Zdravilo Zometa so v dveh glavnih študijah, v kateri je bilo vključenih skupno 287 odraslih bolnikov s hiperkalciemijo, ki jo povzročijo tumorji, primerjali tudi s pamidronatom.
The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases. 
Zmanjševanje izgubljanja kostne mase vpliva na manjšo lomljivost kosti, kar je koristno pri preprečevanju zlomov pri bolnikih z rakom z metastazami v kosteh.
Zometa can be used to prevent bone complications in adults with advanced cancer that is affecting the bone. 
Zdravilo Zometa se lahko uporablja za preprečevanje z okostjem povezanih zapletov pri odraslih z napredovalim rakom, ki prizadene kosti.
This included any bone complications needing treatment with radiotherapy or surgery, any fractures or any spinal compression. 
Gre za kakršne koli kostne zaplete, pri katerih je potrebno zdravljenje z obsevanjem ali operacija, zlome ali pojav spinalne kompresije.
By preventing the breakdown of bones, Zometa also helps to reduce the amount of calcium released into the blood. 
Zdravilo Zometa s preprečevanjem razgradnje kosti pripomore tudi k znižanju ravni kalcija, ki se sprosti v kri.
Zometa was compared with placebo (a dummy treatment) in two of the studies, and with pamidronate (another bisphosphonate) in the third. 
V dveh študijah so ga primerjali s placebom (zdravilom brez zdravilne učinkovine), v tretji pa s pamidronatom (drugim difosfonatom).
What is Zometa used for? 
Za kaj se zdravilo Zometa uporablja?
How has Zometa been studied? 
Kako je bilo zdravilo Zometa raziskano?
How does Zometa work? 
Kako zdravilo Zometa deluje?
How is Zometa used? 
Kako se zdravilo Zometa uporablja?
Appropriate monitoring is advised. 
Priporočljivo je ustrezno spremljanje.
No new safety findings were observed. 
Novih izsledkov o varnosti ni bilo.
Î Don't drive or operate machinery unless you're feeling well. 
Î Ne vozite ali upravljajte strojev, če se ne počutite dobro.
If you are pregnant or could be pregnant, tell your doctor. 
Če ste noseči ali bi lahko bili noseči, o tem obvestite svojega zdravnika.
• if you have type 1 diabetes - this needs different treatment. 
• če imate sladkorno bolezen tipa 1 - potrebno je drugačno zdravljenje
The minimum effective oral dose is approximately 0.6 mg. 
Najmanjši učinkoviti peroralni odmerek je približno 0,6 mg.
Protein binding was greater than 99.5%. 
Vezava na beljakovine je bila več kot 99,5 %.
The clinical relevance of this observation has not been fully elucidated. 
Klinični pomen tega opažanja ni povsem pojasnjen.
It is not known whether breast-feeding will lead to exposure of the infant to medicinal product. 
Ni znano, ali dojenje povzroči izpostavljenost otroka temu zdravilu.
Rarely hypoglycaemic reactions can occur immediately and may be severe and not always easy to correct. 
Redko se lahko nemudoma pojavijo hipoglikemične reakcije, ki so lahko hude in jih ni vedno lahko
There was no significant difference in the effect regardless of whether the drug was taken 30 minutes before or immediately before a meal. 
Učinek zdravila se ni pomembno razlikoval, če je bilo uporabljeno 30 minut pred obrokom ali tik pred njim.
AVAGLIM should be taken once daily shortly before or during a meal (usually the first main meal of the day). 
AVAGLIM je treba vzeti enkrat na dan, tik pred obrokom ali med njim (ponavadi pred ali med prvim dnevnim obrokom).
If a dose is forgotten, the following dose must not be increased. 
Če bolnik pozabi vzeti odmerek, naslednjega odmerka ne sme povečati.
anabolic steroids and male sex hormones, 
anabolni steroidi in moški spolni hormoni,
Packs of 14, 28, 56, 84 or 112 tablets. 
Pakiranja s 14, 28, 56, 84 ali 112 tabletami.
These small changes are not clinically significant and, therefore, it is not necessary to administer rosiglitazone at any particular time in relation to meals. 
Ti majhni spremembi nista klinično pomembni, zato rosiglitazona ni treba uporabljati v kakšnem posebnem časovnem presledku glede na obroke.
Your blood sugar levels may become too high or too low (see ‘Low blood sugar' in Section 4). 
Vrednosti vašega krvnega sladkorja lahko postanejo previsoke ali prenizke (glejte "Nizek krvni sladkor« v poglavju 4).
Similar effects have been seen with other thiazolidinediones. 
Podobne učinke so opažali z drugimi tiazolidindioni.
3.6 (1.8) mg 1995.5 (682.6) mg *Similar relative effective doses (i.e approximately half maximal dose) for other sulphonylureas 
3,6 (1,8) mg 1995,5 (682,6) mg *Podobni relativno učinkoviti odmerki (tj. približno pol največjega odmerka) za druge sulfonilsečnine
If this applies to you, use appropriate contraception to avoid the possibility of an unplanned pregnancy (see ‘Pregnancy and 
Če se to nanaša na vas, morate za preprečitev neželene nosečnosti uporabljati ustrezno obliko kontracepcije (glejte ‘Nosečnost in dojenje'
The inter-subject variability was large, with a 7-fold difference in unbound AUC between patients. 
Interindividualna variabilnost je bila velika in razlika nevezane AUC je bila med bolniki 7-kratna.
The terminal half-life for radioactivity was about 130 h indicating that elimination of metabolites is very slow. 
Terminalni razpolovni čas radioaktivnosti je okrog 130 ur, kar kaže, da je izločanje presnovkov zelo počasno.
You may be at risk of having low blood sugar and need hospital treatment. 
Lahko se vam vrednost krvnega sladkorja zniža tako, da potrebujete bolnišnično zdravljenje.
Î Checking your blood sugar levels regularly is especially important if you are taking any of these medicines, even if you are feeling well 
Î Redno preverjanje vrednosti vašega krvnega sladkorja je potrebno, še posebej karad jemljete katero od teh zdravil, čeprav se počutite dobro
However, this raises no safety concern regarding target or special populations as hepatic impairment is contraindicated and the phase III clinical studies included a considerable number of elderly patients and patients with mild to 
Vendar to ne pomeni nobenih varnostnih zadržkov glede ciljnih ali posebnih populacij, ker okvara jeter pomeni kontraindikacijo, klinične študije III. faze pa so vključile veliko starejših bolnikov in bolnikov z blago do zmerno okvaro ledvic.
If you stop taking Avaglim, your blood sugar will not be controlled, and you may become unwell. 
Če prenehate jemati zdravilo Avanglim, krvni sladkor ne bo več nadzorovan, vaše zdravstveno stanje pa se lahko poslabša.
Avaglim tablets contain a small amount of lactose. 
Avaglim tablete vsebujejo majhno količino laktoze.
In the event of an overdose, it is recommended that appropriate supportive treatment should be initiated as dictated by the patient's clinical status. 
V primeru prevelikega odmerjanja je priporočljivo uvesti ustrezno podporno terapijo, kot jo zahteva bolnikovo klinično stanje.
Don't take extra tablets to make up for a missed dose. 
Ne jemljite dodatnih tablet, da bi tako nadomestili pozabljeni odmerek.
Some of the medicines most likely to do this are: 
Zdravila, ki to lahko povzročijo so:
Avaglim can also strengthen or weaken the effects of medicines to prevent blood clots (anticoagulants such as warfarin). 
Avaglim lahko okrepi ali zmanjša učinke zdravil za preprečevanje tvorbe krvnih strdkov (antikoagulantov, kot je varfarin).
Glimepiride AUC0-t, AUC0-inf and Cmax were increased by 30%, 19% and 55% respectively, on average. 
AUC0-t, AUC0-inf oz. Cmax glimepirida so se v povprečju povečale za 30 %, 19 % oz. 55 %.
For rosiglitazone, Cmax values were decreased by approximately 32% with food. 
Vrednosti Cmax rosiglitazona so se s hrano zmanjšale za približno 32 %.
Î Tell a doctor or pharmacist if you think that Avaglim is not working as it should, particularly if you are taking any other medicines. 
Î Obvestite svojega zdravnika ali farmacevta, če menite, da zdravilo Avaglim ne deluje, kot bi moralo, še posebej, če jemljete katerokoli druga zdravila.
However, rosiglitazone promoted differentiation and reversal of mutagenic changes in human colon cancer cells in vitro. 
Je pa rosiglitazon spodbudil diferenciacijo in preobrat mutagenih sprememb v celicah človeškega raka na kolonu in vitro.
However, the concomitant use of the active substances in patients in clinical studies and in widespread clinical use has not resulted in any unexpected interactions. 
Vendar sočasna uporaba učinkovin v kliničnih študijah in med široko klinično uporabo ni povzročila nepričakovanih medsebojnih delovanj.
− Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached 
− v 60 dneh po pomembnem mejniku (farmakovigilančnem ali povezanem z zmanjševanjem
If ALT levels remain >3X the upper limit of normal, therapy should be discontinued. 
Če raven ALT ostaja > 3-kratno zgornjo normalno mejo, je treba zdravljenje prekiniti.
Overdose of sulphonylureas, including glimepiride, can result in severe life-threatening hypoglycaemia lasting 12 to 72 hours, which may recur after apparent recovery. 
Preveliko odmerjanje sulfonilsečnin, vključno z glimepiridom, lahko povzroči hudo, smrtno nevarno hipoglikemijo, ki traja od 12 do 72 ur in se lahko po navideznem okrevanju ponovi.
10 Hepatitis may progress to liver failure. 
10 Hepatitis lahko napreduje v odpoved jeter.
The possible contribution of fluid retention to weight gain should be individually assessed as rapid and excessive weight gain has been reported very rarely as a sign of fluid retention. 
Možni prispevek zastajanja tekočine k povečanju telesne mase je treba oceniti posamezno, saj so o hitrem in čezmernem povečanju telesne mase kot znaku zastajanja tekočine poročali zelo redko.
Î Tell your doctor as soon as possible if you get any of these symptoms - either for the first time or 
Î Čimprej obvestite svojega zdravnika, če se pojavi katerikoli od teh simptomov - bodisi prvič ali
As with other sulphonylureas, this effect is based on an improvement in responsiveness of pancreatic beta cells to the physiological glucose stimulus. 
Tako kot pri drugih sulfonilsečninah ta učinek temelji na izboljšani odzivnosti pankreatičnih celic beta na fiziološki glukozni stimulus.
Since there is a potential for an increase in the risk of dose-related adverse reactions, a decrease in rosiglitazone dose may be needed. 
Ker obstaja možnost večjega tveganja za neželene reakcije, povezane z odmerkom, utegne biti potrebno zmanjšanje odmerka rosiglitazona.
The major metabolites are the cyclohexyl hydroxy methyl derivative (M1) and the carboxyl derivative (M2). 
Glavna presnovka sta cikloheksilhidroksimetil-derivat (M1) in karboksil-derivat (M2).
Opaque blisters (PVC/PVDC/aluminium). 
Neprosojni pretisni omoti (PVC/PVDC/aluminij).
The chances of this happening may be higher in people, particularly women, taking rosiglitazone for more than one year. 
Verjetnost, da se to zgodi, je lahko večja pri tistih osebah, zlasti ženskah, ki jemljejo zdravilo Avaglim več kot eno leto.
Although the hydroxy metabolite of glimepiride caused a small but significant reduction in serum glucose, it accounts for only a minor part of the total drug effect. 
Čeprav je hidroksi-presnovek glimepirida povzročil majhno, a pomembno znižanje glukoze v serumu, gre na račun tega le manjši del celotnega učinka zdravila.
Manufacturer: Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero, Burgos, 
Izdelovalec: Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero, Burgos,
The dose of the rosiglitazone component can be increased after 8 weeks if required. 
Če je potrebno, je mogoče odmerek rosiglitazona po 8 tednih povečati.
Avaglim can cause reductions in some types of blood cells. 
Avaglim lahko povzroči zmanjšanje števila neketerih vrst krvnih celic.
Rosiglitazone 4 mg should be administered concomitantly with the dose of sulphonylurea already being taken. 
Rosiglitazon 4 mg je treba aplicirati sočasno z odmerkom že uporabljane sulfonilsečnine.
AVAGLIM therapy should be individualised for each patient. 
Zdravljenje z AVAGLIMOM je treba prilagoditi vsakemu bolniku posamezno.
The protein binding of the major metabolite (a para-hydroxy-sulphate) is very high (> 99.99%). 
Vezava glavnega presnovka (parahidroksisulfata) na beljakovine je zelo visoka (> 99,99 %).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, any updated RMP should be submitted at the same time as the following Periodic Safety Update Report 
V skladu s smernicami Odbora za zdravila za uporabo v humani medicini za sisteme za obvladovanje tveganja za zdravila za uporabo v humani medicini mora biti posodobljen načrt za obvladovanje tveganja predložen hkrati z naslednjim posodobljenim poročilom o varnosti zdravila (PSUR).
After intravenous dosing in normal subjects, the volume of distribution was 8.8 l (113 ml/kg), and the total body clearance was 47.8 ml/min. 
Po intravenski uporabi pri zdravih preiskovancih je bil volumen porazdelitve 8,8 l (113 ml/kg), celotni telesni očistek pa 47,8 ml/min.
The antihyperglycaemic activity of rosiglitazone has been demonstrated in a number of animal models of type 2 diabetes. 
Antihiperglikemično delovanje rosiglitazona je dokazano v številnih živalskih modelih diabetesa tipa 2.
Glimepiride is excreted into the milk of lactating rats. 
Glimepirid se izloča v mleku doječih podgan.
An outcome study has not been completed with rosiglitazone, therefore the long-term benefits associated with improved glycaemic control have not been 
Študij izida z rosiglitazonom ni bilo, zato dolgoročne koristi, povezane z boljšo urejenostjo glikemije, niso ugotovljene.
In studies with a maximal duration of three years, rosiglitazone given once or twice daily produced a sustained improvement in glycaemic control (FPG and HbA1c). 
V študijah, ki so trajale največ tri leta, je rosiglitazon, uporabljen enkrat ali dvakrat na dan, povzročil dolgotrajno izboljšanje urejenosti glikemije (GPT in HbA1c).
Avaglim tablets come in different strengths. 
Avaglim tablete so na voljo v različnih jakostih.
• allergic reactions, inflammation of blood vessels (allergic vasculitis) 
• alergijske reakcije, vnetje krvnih žil (alergijski vaskulitis)
*The frequency category for the background incidence of this event, as taken from placebo group data from clinical trials, is 'common'. 
Zelo pogosti *Kategorija pogostnosti glede na osnovno pojavnost tega dogodka, kot izhaja iz podatkov kliničnih preskušanj pri skupinah s placebom, je 'pogosti'.
Undesirable effects observed in animal studies with possible relevance to clinical use were as follows: An increase in plasma volume accompanied by decrease in red cell parameters and increase in heart weight. 
Neželeni učinki, ugotovljeni v študijah na živalih, ki bi lahko bili pomembni za klinično uporabo, so: povečanje količine plazme, ki jo spremlja zmanjšanje parametrov eritrocitov in povečanje mase srca.
Although hormonal imbalance has been seen in preclinical studies (see section 5.3), no significant undesirable effects associated with menstrual disorders have been observed. 
V predkliničnih študijah (glejte poglavje 5.3) so sicer opazili hormonsko neravnovesje, ne pa pomembnih neželenih učinkov, kar zadeva motnje menstruacije.
7 Mild hypersensitivity reactions may develop into serious reactions with dyspnoea, fall in blood 
7 Blage preobčutljivostne reakcije se lahko razvijejo v resne reakcije z dispnejo, padcem krvnega tlaka in
After oral administration, glimepiride is completely (100%) absorbed from the gastrointestinal tract. 
Po peroralni uporabi se glimepirid popolnoma (100 %) absorbira iz prebavil.
If hypoglycaemic symptoms occur, the patient should revert to concomitant therapy and adjust the glimepiride dose as appropriate. 
Če se pojavijo simptomi hipoglikemije, se mora bolnik vrniti na sočasno terapijo in odmerek glimepirida je treba ustrezno prilagoditi.
• Avaglim is not recommended during pregnancy. 
• Uporaba zdravila Avaglim med nosečnostjo ni priporočljiva.
8 Based on what is known of other sulphonylureas, hypoglycaemia may be prolonged. 
8 Glede na to, kar je znanega o drugih sulfonilsečninah, so takšne hipoglikemije lahko dolgotrajne.
• shortness of breath, waking up short of breath at night 
težko dihanje, prebujanje ponoči zaradi težkega dihanja.
Limited data with AVAGLIM is also consistent with this combined adverse reaction profile. 
Tudi omejeni podatki o AVAGLIMU se skladajo s temi kombiniranimi značilnostmi neželenih učinkov.
• increased sensitivity to the sun causing skin rash 
• povečana občutljivost na sončno svetlobo z kožnim izpuščajem
It may be used in non-insulin dependent diabetes mellitus. 
Uporablja se lahko pri sladkorni bolezni, ki ni odvisna od insulina.
In reproductive toxicity studies, administration of rosiglitazone to rats during mid-late gestation was associated with foetal death and retarded foetal development. 
V študijah reproduktivne toksičnosti je bila uporaba rosiglitazona pri podganah med srednjo-pozno gestacijo povezana s fetalnimi smrtmi in zapoznelim razvojem plodov.
Therefore, liver enzymes should be checked prior to the initiation of therapy with AVAGLIM in all patients and periodically thereafter based on clinical judgement. 
Zato je treba pred uvedbo terapije z AVAGLIMOM jetrne encime preveriti pri vseh bolnikih, pozneje pa občasno na osnovi klinične presoje.
Increases in liver weight, plasma ALT (dog only) and fat tissue were also observed. 
Opažali so tudi povečanje mase jeter, zvišanje ALT v plazmi (le pri psih) in porast maščobnega tkiva.